Cellular senescence mediates fibrotic pulmonary disease
Open accessThe DOI matches its Crossref record; 50 of the 52 references it cites were found in a registry or an index; 18 of the 31 sources its claims cite were checked for support.
Abstract
Idiopathic pulmonary fibrosis (IPF) is a fatal disease characterized by interstitial remodelling, leading to compromised lung function. Cellular senescence markers are detectable within IPF lung tissue and senescent cell deletion rejuvenates pulmonary health in aged mice. Whether and how senescent cells regulate IPF or if their removal may be an efficacious intervention strategy is unknown. Here we demonstrate elevated abundance of senescence biomarkers in IPF lung, with p16 expression increasing with disease severity. We show that the secretome of senescent fibroblasts, which are selectively killed by a senolytic cocktail, dasatinib plus quercetin (DQ), is fibrogenic. Leveraging the bleomycin-injury IPF model, we demonstrate that early-intervention suicide-gene-mediated senescent cell ablation improves pulmonary function and physical health, although lung fibrosis is visibly unaltered. DQ treatment replicates benefits of transgenic clearance. Thus, our findings establish that fibrotic lung disease is mediated, in part, by senescent cells, which can be targeted to improve health and function.
Overview
CoChat Summary
## TL;DR
This study links cellular senescence to idiopathic pulmonary fibrosis (IPF) by showing that senescence markers rise with disease severity in human lung tissue and that senescent fibroblast secretions are profibrotic. In a bleomycin mouse model, clearing senescent cells improved lung function and physical health, and dasatinib plus quercetin (DQ) reproduced the benefits of transgenic senescent-cell ablation.
## Key findings
- In human IPF lung samples, CDKN2A (p16) was significantly upregulated and increased with disease severity; higher pulmonary p16 expression correlated with reduced FVC, diffusion capacity, and SF-12 physical component score.
- In IPF tissue, p16-positive epithelial cells and fibroblasts were found in fibroblastic foci and honeycomb lung, and TAF-positive cells / γH2A.X foci were significantly increased relative to controls.
- In the bleomycin mouse model, lung injury increased whole-lung p16 expression by threefold, and SASP-related transcripts including Mcp1, Il6, Mmp12, Col1a1, and Tgfβ rose after bleomycin exposure.
- Senescent fibroblast conditioned medium was fibrogenic in vitro: it increased αSMA positivity to 62% vs 21% with control conditioned medium, increased traction forces, and induced fibrosis genes such as ACTA2, COL1A1, COL1A2, and FN1.
- In mice, senescent-cell clearance improved pulmonary/physical outcomes: Penh rose about twofold after bleomycin and was diminished by AP or DQ; lung compliance fell by 40% in vehicle-treated bleomycin mice but only 15% with AP or DQ; body weight loss averaged 3.6 g with vehicle vs about 1.6 g with AP/DQ; treadmill distance to exhaustion was >37% further with AP/DQ than vehicle.
- The paper states that histological fibrosis reductions did not reach statistical significance, despite functional benefits.
## Methods
- Human data came from LTRC control and IPF lung tissue samples, including microarray and RNA-seq datasets; the paper reports IPF n=27 and control n=10 for p16 immunohistochemistry, and transcriptome analyses stratified by FVC severity.
- The mouse study used male Ink-Attac mice given aerosolized intratracheal bleomycin (2 U/kg) or PBS, then randomized to AP20187, dasatinib plus quercetin (DQ), or vehicle at either an early prevention timepoint or a later treatment timepoint.
- Analyses included FACS of lung fibroblasts, epithelial cells, and endothelial cells, immunohistochemistry / immunofluorescence, conditioned-medium assays in IMR90 fibroblasts, traction force microscopy, RT-PCR, and statistical modeling with regression and multiple-comparison correction.
## Limitations
- The paper states that the bleomycin model spontaneously resolves, with resolution varying by factors such as genetic background and microbiome, which limits interpretation of late-stage effects.
- The authors state that they could not disentangle senescence-dependent from senescence-independent events governing fibrosis resolution.
- Lung fibrosis histology did not improve significantly after senescent-cell clearance, despite functional gains; the paper itself notes this may reflect the short time course and heterogeneity of the bleomycin model.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
13 Valid · 0 Not valid · 8 Not checked · 94 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Through secretion of the senescence-associated secretory phenotype (SASP), a broad repertoire of cytokines, chemokines, matrix remodelling proteases and growth factors, senescent cells paracrinely promote proliferation and tissue deterioration8.”
§ Cellular senescence mediates fibrotic pulmonary disease > Abstract
What the sources say
- Partly supportedcites [8] van Deursen, J. M. The role of senescent cells in ageing. Nature 509, 439–446 (2014). sourceExperimental — accuracy not yet measured
In “Senescence is a multi-step evolving process” (page unavailable), the paper says SASP-mediated paracrine signalling affects cell proliferation. In “Senescence in ageing and age-related disease” (page unavailable), it says SASP components are thought to promote proliferation of neoplastic cells and may intensify age-related tissue deterioration. The citing sentence presents those qualified effects as established and general. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Cellular senescence is an evolutionarily conserved state of stable replicative arrest induced by pro-ageing stressors also implicated in IPF pathogenesis, including telomere attrition, oxidative stress, DNA damage and proteome instability.”
§ Cellular senescence mediates fibrotic pulmonary disease > Abstract
What the sources say
- Partly supportedcites [8] van Deursen, J. M. The role of senescent cells in ageing. Nature 509, 439–446 (2014). sourceExperimental — accuracy not yet measured
The Abstract and 'Senescence is a multi-step evolving process' describe growth arrest, including a transition to stable cell-cycle arrest. 'Causes and effector pathways of senescence' identifies telomere erosion, DNA lesions, reactive oxygen species and proteotoxic stress as senescence-related stressors. The cited passages do not establish that senescence is evolutionarily conserved or that these stressors are implicated in IPF pathogenesis; the paper also distinguishes replicative senescence from other forms of senescence. (LLM, conf=0.86)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Critically, impaired capacity to resolve fibrotic bleomycin injury has been associated with accumulation of apoptosis-resistant, senescent myofibroblasts3.”
§ Cellular senescence mediates fibrotic pulmonary disease > Results > Senescent cell retention impairs fibrosis resolution Taken together, our in vivo results strongly support the hypothesis that elimination of senescent cells improves fibrotic pulmonary disease when treatment is initiated at the onset of pathogenesis. We next sought to test the clinically important question of whether senescent cell clearance provides comparable benefit when initiated at a timepoint when pathology has fully developed. Ink-Attac mice contained a strong senescent signature in lung fibroblasts and epithelial cells 2 weeks post-bleomycin challenge (Fig. 2), a timepoint of well-established fibrotic remodelling in the lung15. Accordingly, we administered a single dose of bleomycin or PBS through aerosolized intratracheal administration to Ink-Attac mice. Two weeks post challenge, we randomized bleomycin-exposed mice to AP, DQ or vehicle treatment groups based on change in body weight and non-invasively measured airway resistance (Penh). Mice were treated for 2 weeks and were killed 4 weeks following bleomycin or PBS exposure (Fig. 5a). Body weight monitoring revealed that, similar to our previous experiments (Fig. 4f), mice that received bleomycin lost substantial body mass, relative to mice that received PBS. Upon treatment initiation on day 14, mean body weight of mice treated with AP plateaued, while vehicle-treated, bleomycin-exposed counterparts continued to lose weight (Fig. 5a), suggestive of physical benefit afforded by senescent cell clearance, even when treatment is initiated in later-stage disease. Spontaneous resolution is an inherent limitation of the bleomycin IPF model, with the rate and variability of bleomycin-induced pathology resolution dependent on complex factors, including genetic background and the microbiome3839. Indeed, both endpoint compliance (Supplementary Fig. 6) and comparison of Penh airway resistance at endpoint (4 weeks post challenge) to measures taken at the treatment randomization timepoint (2 weeks post challenge) revealed appreciable, albeit variable, improvement in all bleomycin-exposed groups, including vehicle-treated mice, with AP-treated mice showing greatest improvement (Fig. 5b). Thus, in our hands, the 3–4-week-period following a single bleomycin exposure represents a pivotal window of natural resolution (Figs 4 and 5a,b). Critically, impaired capacity to resolve fibrotic bleomycin injury has been associated with accumulation of apoptosis-resistant, senescent myofibroblasts3. As we were unable to disentangle senescence-dependent and -independent events governing resolution, we queried whether p16 expression, a measure of senescent burden, was associated with indicators of disease persistence. Impaired lung function, as measured by endpoint airway resistance (Penh) (Fig. 5c) and airway compliance (Fig. 5d), correlated significantly with p16 transcript abundance. This finding is consistent with associations drawn in humans, in which increased p16 expression correlated significantly with reduced FVC, pulmonary diffusion capacity and physical function (Supplementary Fig. 1). Similarly, in bleomycin-exposed mice, expression of the inflammatory and fibrogenic SASP factors Mcp1 (Fig. 5e), Pai1 (Fig. 5f), Mmp10 (Fig. 5g) and Col1a1 (Fig. 5h) robustly correlated with p16 transcriptional activation. These results further support the notion that the presence and activities of senescent cells may dictate resolution capacity following bleomycin-induced pathology.
What the sources say
- Supportedcites [3] Hecker, L. et al. Reversal of persistent fibrosis in aging by targeting Nox4-Nrf2 redox imbalance. Sci. Transl. Med. 6, 231ra247 (2014). source
The Introduction states that aged mice have impaired fibrosis resolution associated with senescent, apoptosis-resistant myofibroblasts. The Results identify bleomycin as the lung-injury model and report accumulation of senescent myofibroblasts in aged mice with persistent fibrosis. Page numbers are not provided in our copy. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Senescence was confirmed by expression profiling (p16, SASP factors) and/or SA-β-gal staining32 21 days post radiation.”
§ Cellular senescence mediates fibrotic pulmonary disease > Methods > Cell culture For experiments employing radiation-induced senescence, IMR90 (passages 5–7; ATCC, catalogue number CCL-186) and primary human fibroblasts (passages 3–6) were exposed to 10 Gy radiation or sham conditions using a RS2000 X-Ray Irradiator (RAD Source Technologies, Suwanee, GA). Normal bronchial epithelial cells (passages 4–7, Lot 7F3000, Lonza, Walkersville, MD) were exposed to 5 Gy or sham conditions. Senescence was confirmed by expression profiling (p16, SASP factors) and/or SA-β-gal staining32 21 days post radiation. For SA-β-gal staining, cells were fixed for 10 min in 2% formaldehyde+0.2% glutaraldehyde in PBS at room temperature. Cells were rinsed with PBS and incubated overnight in SA-β-gal staining solution containing the following: 1 mg ml−1 X-gal, 40 mM citric acid/sodium phosphate buffer pH 6.0, 5 mM potassium ferrocyanide, 5 mM potassium ferricyanide, 150 mM sodium chloride and 2 mM magnesium chloride in water. Cells were then rinsed in PBS and stored at 4 °C until imaging. Media applied 20 days post irradiation (or sham) was collected 24 h later and was diluted with NCM to reflect equivalent source cell concentrations. ProcartaPlex immunoassays (Affymetrix eBioscience) were used for CM secretome composition assessment, according to the manufacturer's specifications. Non-irradiated IMR90 cells (passages 5–7) were treated with NCM, NCM+2 ng ml−1 TGFβ, CCM or SASP-CM and applied to downstream analyses as indicated. Primary human fibroblasts collected from human patients were authenticated through αSMA staining. For senolytic treatment, sham and irradiated primary human fibroblasts were treated with indicated concentrations of DQ or navitoclax for 3 days, starting at day 20 post irradiation or sham exposure. Cell viability after drug treatment was measured by ATPLite Kits (PerkinElmer; Waltham, MA) performed according the manufacturer's instructions. Luminescence was read using a multi-scan plate reader (Fisher). For experiments utilizing etoposide-induced senescence, IMR90 human lung fibroblasts (passage 10; ATCC) were treated for 48 h with 20 μM etoposide (Enzo Life Sciences, Farmingdale, NY). Etoposide was removed and replaced with fresh media. Six days after etoposide removal, approximately 60% of IMR90 cells were SA-β-gal positive. Cells were treated for 48 h with 20 μM D+15 μM Q or 10 μM navitoclax (or untreated control) and the percentage of SA-β-gal-positive cells was determined using a C12FDG-based senescence assay described as follows46. Briefly, etoposide-treated senescent IMR90 cells were seeded at a concentration of 5 × 103 cells per well in 96-well plates 24 h before treatment. Following addition of the drugs, the cells were incubated for 48 h under 20% O2 oxygen conditions. For fluorescence analysis of SA-β-gal activity, cells were incubated for 1 h with 100 nM Bafilomycin A1 (Calbiochem, San Diego, CA). Next, 10 μM C12FDG (Setareh Biotech, Eugene, OR) was added to the culture medium and the cells were incubated for 1.5–2 h. Ten minutes before analysis, the DNA intercalating Hoechst dye (2 μg ml−1) was added to the cells. For quantitative analysis of cell number (Hoechst staining) and number of C12FDG-positive senescent cells, a laser-based line scanning confocal imager IN Cell 6000 Analyzer was used. All samples were analysed in duplicate with three to five fields per well.
What the sources say
- Partly supportedcites [32] Baker, D. J. et al. Naturally occurring p16(Ink4a)-positive cells shorten healthy lifespan. Nature 530, 184–189 (2016). sourceExperimental — accuracy not yet measured
In “ATTAC clears senescent adipocyte progenitor cells” (page unavailable), the paper identifies cells using p16 expression, other senescence markers, and SAβ-Gal staining. It studies naturally occurring senescent cells, however, and does not support the claim’s 21-day post-radiation condition. (LLM, conf=0.86)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Importantly, CM collected from irradiated bronchiolar epithelial cells did not activate a fibrogenic response, as measured by αSMA fibrotic activation of naive IMR90 cells (Supplementary Fig. 2), suggesting that cell-type-specific SASP composition may differentially affect pathological phenotypes within the lung.”
§ Cellular senescence mediates fibrotic pulmonary disease > Results > The secretome of senescent fibroblasts is profibrotic
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
61 more claims
Create a free account to see all 115 claims and to verify the 5 references still open.
- It may state two separate claims as one. 29
- Probably not a substantial claim. 26
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This is in agreement with a recent report showing that the removal of senescent cells expressing high levels of p16INK4a can lead to fibrosis in mice101, whereas small-molecule senolytics appear to reduce fibrosis in several mouse tissues22,71,73,75,102.”
From Cellular senescence and senolytics: the path to the clinic (2022) · cites this paper as [71]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“in a mouse model of idiopathic pulmonary fibrosis (IPF), D + Q treatment improved lung compliance and reduced frailty71.”
From Cellular senescence and senolytics: the path to the clinic (2022) · cites this paper as [71]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Patients with IPF accumulate TAFs and senescence markers in lungs that increase with disease severity and activate SASP52.”
From Telomere dysfunction in ageing and age-related diseases (2022) · cites this paper as [52]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The use of various natural flavonoids, including quercetin and fisetin, either alone or in combination with dasatinib, a pan-tyrosine kinase inhibitor, can stimulate senolysis in a variety of contexts in vitro and in vivo199,207–210.”
From Cellular senescence in ageing: from mechanisms to therapeutic opportunities (2021) · cites this paper as [199]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“consistent with enhanced paracrine signaling from increased numbers of senescent neighbors and with established features of epithelial aging.23,25,32–35”
From SenCat: Cataloging human cell senescence through multi-omic profiling of multiple senescent primary cell types (2026) · cites this paper as [33]
Experimental — accuracy not yet measured
35 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Smyth, G. K. (2004) · Statistical Applications in Genetics and Molecular Biology · doi:10.2202/1544-6115.1027 · Cited by 11,829
Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders
Baker, D. J., Wijshake, T., Tchkonia, T., LeBrasseur, N. K., Childs, B. G., van de Sluis, B., Kirkland, J. L., & van Deursen, J. M. (2011) · Nature · doi:10.1038/nature10600 · Cited by 3,670
Self-citationNaturally occurring p16Ink4a-positive cells shorten healthy lifespan
Baker, D. J., Childs, B. G., Durik, M., Wijers, M. E., Sieben, C. J., Zhong, J., A. Saltness, R., Jeganathan, K. B., Verzosa, G. C., Pezeshki, A., et al. (2016) · Nature · doi:10.1038/nature16932 · Cited by 2,876 · cited 2×
“Attenuation of age-related pathologies and extension of lifespan in chronologically aged mice has been demonstrated using the same transgenic strategy 32–34 , and improvements in lung structure and function in aged mice have recently been demonstrated using a similar suicide-gene strategy 20 .”
Idiopathic Pulmonary Fibrosis: Diagnosis and Treatment: International Consensus Statement
(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.2.ats3-00 · Cited by 2,628
The role of senescent cells in ageing
van Deursen, J. M. (2014) · Nature · doi:10.1038/nature13193 · Cited by 2,623
The Achilles' heel of senescent cells: from transcriptome to senolytic drugs
Zhu, Y., Tchkonia, T., Pirtskhalava, T., Gower, A. C., Ding, H., Giorgadze, N., Palmer, A. K., Ikeno, Y., Hubbard, G. B., Lenburg, M., et al. (2015) · Aging Cell · doi:10.1111/acel.12344 · Cited by 2,584 · cited 2×
“An alternative approach to transgenic senescent cell clearance is senolytics 21,22 , which may be a tractable treatment option for humans.”
Self-citationDesmoulière, A., Geinoz, A., Gabbiani, F., & Gabbiani, G. (1993) · The Journal of cell biology · doi:10.1083/jcb.122.1.103 · Cited by 2,243
King, T. E., Pardo, A., & Selman, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60052-4 · Cited by 2,194
An Essential Role for Senescent Cells in Optimal Wound Healing through Secretion of PDGF-AA
Demaria, M., Ohtani, N., Youssef, S. A., Rodier, F., Toussaint, W., Mitchell, J. R., Laberge, R.-M., Vijg, J., Van Steeg, H., Dollé, M. E. T., et al. (2014) · Developmental Cell · doi:10.1016/j.devcel.2014.11.012 · Cited by 2,045
Senescence of Activated Stellate Cells Limits Liver Fibrosis
Krizhanovsky, V., Yon, M., Dickins, R. A., Hearn, S., Simon, J., Miething, C., Yee, H., Zender, L., & Lowe, S. W. (2008) · Cell · doi:10.1016/j.cell.2008.09.015 · Cited by 2,027
Cited by
Items 601–700 of 1,619
Cranberries – potential benefits in patients with chronic kidney disease
Alvarenga, L., Borges, N. A., Moreira, L. D. S. G., Teixeira, K. T. R., Carraro-Eduardo, J. C., Dai, L., Stenvinkel, P., Lindholm, B., & Mafra, D. (2019) · Food & Function · doi:10.1039/c9fo00375d · Cited by 31
Huang, Q., Chen, Y., Shen, S., Wang, Y., Liu, L., Wu, S., Xu, W. D., Zhao, W., Lin, M., & Wu, J. (2020) · Aging · doi:10.18632/aging.102978 · Cited by 34
“There is an emerging body of evidence suggesting that anti-aging treatment is a novel therapeutic approach for IPF [9].”
BackgroundRising from the ashes: cellular senescence in regeneration
Walters, H., & Yun, M. H. (2020) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2020.06.002 · Cited by 32
Fibroblasts and their responses to chronic injury in pulmonary fibrosis
Wu, B., Tang, L. F., & Kapoor, M. (2020) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2020.12.003 · Cited by 37
Senescence Alterations in Pulmonary Hypertension
Roger, I., Milara, J., Belhadj, N., & Cortijo, J. (2021) · Cells · doi:10.3390/cells10123456 · Cited by 40
IL-11 system participates in pulmonary artery remodeling and hypertension in pulmonary fibrosis
Milara, J., Roger, I., Montero, P., Artigues, E., Escrivá, J., & Cortijo, J. (2022) · Respiratory Research · doi:10.1186/s12931-022-02241-0 · Cited by 33
Trials and Treatments: An Update on Pharmacotherapy for Idiopathic Pulmonary Fibrosis
Thong, L., McElduff, E. J., & Henry, M. T. (2023) · Life · doi:10.3390/life13020486 · Cited by 37
Sirtuins and Accelerated Aging in Scleroderma
Wyman, A. E., & Atamas, S. P. (2018) · Current Rheumatology Reports · doi:10.1007/s11926-018-0724-6 · Cited by 34
Salvia officinalisattenuates bleomycin-induced oxidative stress and lung fibrosis in rats
Bahri, S., Ali, R. B., Nahdi, A., et al. (2019) · Nutrition and Cancer · doi:10.1080/01635581.2019.1675724 · Cited by 31
“model of bleomycin-induced pulmonary fibrosis in wistar rats, which is the most extensively animal model of IPF used by several research teams worldwide, by producing similar pathological features to IPF patients (10).”
BackgroundYang, J.-J., Zhao, S.-L., Zhang, X., Ma, Y., & Jiang, J. (2023) · Industrial Crops and Products · doi:10.1016/j.indcrop.2023.116903 · Cited by 30
Ruan, Z., Li, D., Huang, D., Liang, M., Xu, Y., Qiu, Z., & Chen, X. (2023) · BMJ Open · doi:10.1136/bmjopen-2023-076746 · Cited by 35
Targeting iron-metabolism:a potential therapeutic strategy for pulmonary fibrosis
Sun, Y., Ren, Y., Song, L., Wang, Y.-Y., Li, T., Wu, Y., Li, L., & Yang, Z. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116270 · Cited by 35
Targeting senescent cells for the treatment of age-associated diseases
Suda, M., Tchkonia, T., Kirkland, J. L., & Minamino, T. (2024) · The Journal of Biochemistry · doi:10.1093/jb/mvae091 · Cited by 39
Self-citationPI3K/Akt in IPF: untangling fibrosis and charting therapies
Bhatt, J., Ghigo, A., & Hirsch, E. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1549277 · Cited by 40
Hadjicharalambous, M. R., Roux, B. T., Csomor, E., Feghali‐Bostwick, C. A., Murray, L. A., Clarke, D. L., & Lindsay, M. A. (2019) · Scientific Reports · doi:10.1038/s41598-019-42292-w · Cited by 30
miR-1468-3p Promotes Aging-Related Cardiac Fibrosis
Lin, R., Rahtu‐Korpela, L., Magga, J. M., Ulvila, J., Swan, J., Kemppi, A., Pakanen, L., Porvari, K., Huikuri, H. V., Junttila, J. M., et al. (2020) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2020.04.001 · Cited by 31
“They further demonstrated that the senescent fibroblasts are fibrogenic and promote IPF, and removal of senescent fibroblasts improved pulmonary function in a bleomycin-induced lung fibrosis model.(43) In cardiac disease models, senescent CFs accumulate in the heart both after myocardial infarction(44) and thoracic ao…”
BackgroundInfluentialNano-Based Theranostic Tools for the Detection and Elimination of Senescent Cells
Adamczyk‐Grochala, J., & Lewińska, A. (2020) · Cells · doi:10.3390/cells9122659 · Cited by 32
Phospholipase A2 receptor 1 promotes lung cell senescence and emphysema in obstructive lung disease
Beaulieu, D., Attwe, A., Breau, M., Lipskaia, L., Marcos, É., Born, E., Huang, J. L., Abid, S., Dérumeaux, G., Houssaini, A., et al. (2021) · European Respiratory Journal · doi:10.1183/13993003.00752-2020 · Cited by 32
Min, S., Zhu, M., Mao, X., Li, W., Wei, T., Mei, M., Zhang, Y., Wu, L., Yu, G., & Cong, X. (2021) · Arthritis & Rheumatology · doi:10.1002/art.42052 · Cited by 34
“The lung alveolar epithelium exhibits increased p16 and p21 expression and greater SA β-gal activity in idiopathic pulmonary fibrosis patients and in a mouse model of bleomycin-induced lung injury (32,33).”
BackgroundHeinzelmann, K., Lehmann, M., Gerckens, M., Noskovičová, N., Frankenberger, M., Lindner, M., Hatz, R. A., Behr, J., Hilgendorff, A., Königshoff, M., et al. (2018) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00439.2017 · Cited by 36
Mixing old and young: enhancing rejuvenation and accelerating aging
Lau, A., Kennedy, B. K., Kirkland, J. L., & Tullius, S. G. (2019) · Journal of Clinical Investigation · doi:10.1172/jci123946 · Cited by 29
Self-citationYou Say You Want a Resolution (of Fibrosis)
Atabai, K., Yang, C. D., & Podolsky, M. J. (2020) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2020-0182tr · Cited by 31
“regeneration because the retention of senescent cells is associated with persistence of fibrosis in the lung (171, 172), heart (173), skin (174), liver (175), and kidney”
BackgroundRoth‐Walter, F., Adcock, I. M., Benito‐Villalvilla, C., Bianchini, R., Bjermer, L. H., Caramori, G., Cari, L., Chung, K. F., Diamant, Z., Eguíluz‐Gracia, I., et al. (2023) · Allergy · doi:10.1111/all.15977 · Cited by 35
Conover, C. A., & Oxvig, C. (2024) · Endocrine Reviews · doi:10.1210/endrev/bnae029 · Cited by 39
Ahmed, R., Ashimori, A., Iwamoto, S., Matsui, T., Nakahata, Y., & Bessho, Y. (2019) · Aging · doi:10.18632/aging.101794 · Cited by 32
“Recent studies demonstrated that pharmacological or genetic eliminations of senescent cells from aging mice extend median lifespan, delayed tumorigenesis and attenuated progression of already established agerelated disorders [4-10].”
Kidney Allograft Fibrosis: Diagnostic and Therapeutic Strategies
Saritas, T., & Kramann, R. (2021) · Transplantation · doi:10.1097/tp.0000000000003678 · Cited by 32
Pathology, Radiology, and Genetics of Interstitial Lung Disease in Patients With Shortened Telomeres
Cecchini, M. J., Tarmey, T., Ferreira, A. J., Mangaonkar, A. A., Ferrer, A., Patnaik, M. M., Wylam, M. E., Jenkins, S. M., Spears, G. M., Yi, E. S., et al. (2021) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001725 · Cited by 30
Targeting Aging: Lessons Learned From Immunometabolism and Cellular Senescence
Martin, D. E., Torrance, B. L., Haynes, L., & Bartley, J. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.714742 · Cited by 32
Epithelial senescence in idiopathic pulmonary fibrosis is propagated by small extracellular vesicles
Asghar, S., Monkley, S. J., Smith, D. J. F., Hewitt, R. J., Grime, K., Murray, L. A., Overed-Sayer, C. L., & Molyneaux, P. L. (2023) · Respiratory Research · doi:10.1186/s12931-023-02333-5 · Cited by 35
“In IPF and fibrotic disease models, markers of senescence are increased in fibroblasts and epithelial cells [14, 16].”
BackgroundCellular senescence is a key mediator of lung aging and susceptibility to infection
Torrance, B. L., & Haynes, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1006710 · Cited by 32
“IPF has been more definitively shown to be primarily driven by senescence (9) via similar mechanisms and are comprehensively reviewed elsewhere (10).”
BackgroundAdvances in cellular senescence in idiopathic pulmonary fibrosis (Review)
Han, S., Lu, Q., & Liu, X. (2023) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2023.11844 · Cited by 34
“Over the past decades, scientists have explored the mecha‑ nisms that lead to aging, damage and fibrosis of lung cells and have yielded useful insights (3,5,6,9,12,15,19,53,95).”
PAI-1 Regulation of p53 Expression and Senescence in Type II Alveolar Epithelial Cells
Rana, T., Jiang, C., Banerjee, S., Yi, N., Zmijewski, J. W., Liu, G., & Liu, R.-M. (2023) · Cells · doi:10.3390/cells12152008 · Cited by 32
Wei, X., Zheng, Z., Liu, M., Yang, Z., Xie, E., Lin, J., Gao, Y., Tan, R., She, Z., Ma, J., et al. (2023) · Acta Biomaterialia · doi:10.1016/j.actbio.2023.10.015 · Cited by 32
Yang, M. M., Lee, S., Neely, J. A., Hinchcliff, M., Wolters, P. J., & Sirota, M. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1326922 · Cited by 35
Dual Barrier‐Penetrating Inhaled Nanoparticles for Enhanced Idiopathic Pulmonary Fibrosis Therapy
Yang, M., Han, M., Ling, T., Bi, Y., Li, X., Jeong, J., Wang, Y., & Jiang, H. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202315128 · Cited by 30
p21 regulates expression of ECM components and promotes pulmonary fibrosis via CDK4 and Rb
Papismadov, N., Levi, N., Roitman, L., Agrawal, A., Ovadya, Y., Cherqui, U., Yosef, R., Akiva, H., Gal, H., & Krizhanovsky, V. (2024) · The EMBO Journal · doi:10.1038/s44318-024-00246-7 · Cited by 34
“…of p21 was shown to have anti-fi brotic effects in lung fi brosis pathology (Inoshima et al, 2004), other studies have shown that p21-positive senescent cells contribute to the progression of lung fi brosis and chronic obstructive pulmonary disease (COPD) (Liu and Liu, 2020; Schafer et al, 2017).”
InfluentialImmunotherapy and senolytics in head and neck squamous cell carcinoma: phase 2 trial results
Liu, N., Wu, J., Deng, E., Zhong, J., Wei, B., Cai, T., Xie, Z., Duan, X., Fu, S., Osei-Hwedieh, D. O., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03873-7 · Cited by 47
“In murine models, D + Q alleviates multiple senescencerelated pathologies 25–29 .”
Self-citationTreatment with the senolytics dasatinib/quercetin reduces SARS‐CoV ‐2‐related mortality in mice
Pastor‐Fernández, A., Bertos, A. R., Sierra‐Ramírez, A., del Moral‐Salmoral, J., Merino, J., de Ávila, A. I., Olagüe, C., Villares, R., González‐Aseguinolaza, G., Rodríguez, M. Á., et al. (2023) · Aging Cell · doi:10.1111/acel.13771 · Cited by 28
“…as a decreased burden of other clinical symptoms associated with COVID- 19, demonstrating a significant improvement in the overall health of mice treated with D/Q, and in agreement with previous reports (Palmer et al., 2019; Schafer et al., 2017; Sierra- Ramirez et al., 2020; Zhang et al., 2019).”
BackgroundResultCellular Senescence in Chronic Obstructive Pulmonary Disease: Multifaceted and Multifunctional
Antony, V. B., & Thannickal, V. J. (2018) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2018-0061ed · Cited by 27
Effect of menopausal hormone therapy on proteins associated with senescence and inflammation
Faubion, L. L., White, T. A., Peterson, B. J., Geske, J. R., LeBrasseur, N. K., Schafer, M. J., Mielke, M. M., & Miller, V. M. (2020) · Physiological Reports · doi:10.14814/phy2.14535 · Cited by 29
“Functionally, SASPs correlate positively with frailty and adverse cardiovascular surgical and cancer outcomes (Schafer et al., 2017).”
BackgroundSelf-citationEscriche‐Navarro, B., Garrido, E. M. N., Sancenón, F., García‐Fernández, A., & Martínez‐Máñez, R. (2024) · Acta Biomaterialia · doi:10.1016/j.actbio.2024.01.002 · Cited by 29
Inflammation and tumor immune escape in response to DNA damage
Nihira, N. T., Kudo, R., & Ohta, T. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.02.005 · Cited by 33
Khaidizar, F. D., Nakahata, Y., Kume, A., Sumizawa, K., Kohno, K., Matsui, T., & Bessho, Y. (2017) · Genes to Cells · doi:10.1111/gtc.12542 · Cited by 31
“…or genetically, from aging mice extended median lifespan, delayed tumorigenesis and attenuated progression of already established age- related disorders (Baar et al., 2017; Baker et al., 2011, 2016; Chang et al., 2016; Hashimoto et al., 2016; Schafer et al., 2017; Yosef et al., 2016).”
BackgroundChen, B., Chai, Q., Xu, S., Li, Q., Wu, T., Chen, S., & Wu, L. (2020) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2020.111070 · Cited by 28
Telomeres in toxicology: Occupational health
Shoeb, M., Meier, H. C. S., & Antonini, J. M. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107742 · Cited by 33
Wicher, S. A., Roos, B. B., Teske, J. J., Fang, Y. H., Pabelick, C. M., & Prakash, Y. S. (2021) · PLoS ONE · doi:10.1371/journal.pone.0254710 · Cited by 30
“Upon acquisition of tissues, relevant clinical data PLOS ONE | https://doi.org/10.1371/journal.pone.0254710 July 29, 2021 2 / 19 Abbreviations: ASM, Airway smooth muscle; ACh, Acetylcholine; β-gal, Beta galactosidase; Ca2+, Calcium; [Ca2+]i, Intracellular calcium concentration; CCL2, monocyte chemoattractant protein 1…”
BackgroundInfluentialSelf-citationArginine Methyltransferase PRMT1 Regulates p53 Activity in Breast Cancer
Liu, L.-M., Tang, Q., Hu, X., Zhao, J., Zhang, Y., Ying, G., & Zhang, F. (2021) · Life · doi:10.3390/life11080789 · Cited by 31
“SA-β-gal staining was carried out as reported previously [21].”
MethodFunctional Pdgfra fibroblast heterogeneity in normal and fibrotic mouse lung
Trempus, C. S., Papas, B. N., Sifre, M. I., Bortner, C. D., Scappini, E., Tucker, C. J., Xu, X., Johnson, K. L., Deterding, L. J., Williams, J. G., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.164380 · Cited by 33
“IPF is a disease of the aged lung, and FBs in IPF lungs have a senescent phenotype that has been shown to contribute to the development of fibrosis (61–64).”
BackgroundAccumulation of senescent cells in the stroma of aged mouse ovary
Maruyama, N., FUKUNAGA, I., Tomoaki, K. O. G. O., Endo, T., Fujii, W., Kanai‐Azuma, M., Naito, K., & Sugiura, K. (2023) · Journal of Reproduction and Development · doi:10.1262/jrd.2023-021 · Cited by 33
“Senescent cell-induced fibrosis is also implicated in idiopathic pulmonary fibrosis, as locally induced senescence in the lung causes lung fibrosis and defective physical function in a mouse model, whereas clearing senescent cells improves pulmonary function in the same model [61].”
BackgroundPerspectives of PDE inhibitor on treating idiopathic pulmonary fibrosis
Yang, X., Xu, Z., Hu, S., & Shen, J. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1111393 · Cited by 33
“Senescence is an important factor in the process of pulmonary fibrosis (Schafer et al., 2017; Justice et al., 2019; Otoupalova et al., 2020; Spagnolo et al., 2021a; Yao et al., 2021).”
BackgroundShi, H., Deng, L., Zhou, Y., Yu, H., Huang, X. X., Chen, M., Yang, L., & Dong, J. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.116691 · Cited by 27
Zhang, J. Y., Li, C., Liu, H., Wang, Q., Xu, A. Y., Shah, K., Qi, L., Wang, Z., Zhang, X., Huang, C., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114066 · Cited by 44
Targeting p16INK4a Promotes Lipofibroblasts and Alveolar Regeneration after Early-Life Injury
Zysman, M., Baptista, B. R., Essari, L.-A., Taghizadeh, S., de Ménonville, C. T., Giffard, C., Issa, A., Franco‐Montoya, M., Breau, M., Souktani, R., et al. (2020) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201908-1573oc · Cited by 29
Senolytics: Targeting Senescent Cells for Age-Associated Diseases
Al‐Naggar, I. M., Kuchel, G. A., & Xu, M. (2020) · Current Molecular Biology Reports · doi:10.1007/s40610-020-00140-1 · Cited by 32
“D+Q has moved to human trials of incurable diseases where SnCs have been found to play a causal role such as idiopathic pulmonary fibrosis (IPF), diabetic kidney disease (DKD) and early stage symptomatic tau+ Alzherimer’s disease to determine safety, tolerability and effectiveness (Figure 1) [42, 43, 34, 44, 37, 45, 4…”
BackgroundMolecular Mechanisms to Target Cellular Senescence in Hepatocellular Carcinoma
Mittermeier, C., Konopa, A., & Muehlich, S. (2020) · Cells · doi:10.3390/cells9122540 · Cited by 30
Sensitization of the UPR by loss of PPP1R15A promotes fibrosis and senescence in IPF
Monkley, S. J., Overed-Sayer, C. L., Parfrey, H., Rassl, D. M., Crowther, D. C., Escudero‐Ibarz, L., Davis, N., Carruthers, A. M., Berks, R., Coetzee, M., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-00769-7 · Cited by 28
Integrative omics analysis identifies biomarkers of idiopathic pulmonary fibrosis
Zheng, P., Sun, S., Wang, J., Cheng, Z. J., Lei, K. C., Xue, M., Zhang, T., Huang, H., Zhang, X. D., & Sun, B. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-04094-0 · Cited by 30
“As a result, 91 datasets (52 IPF tissues vs. 39 healthy tissues) from four RNA-sequencing projects (GSE52463 [32], GSE83717 [33], GSE92592 [34], and GSE99621 [12]) were identified and downloaded using NCBI’s sratoolkit (http:// ncbi. github. io/ sra- tools/, version 2.9.6-1).”
MethodInfluentialCirculating Mitochondrial DNA and Inter-Organelle Contact Sites in Aging and Associated Conditions
Picca, A., Guerra, F., Calvani, R., Romanò, R., Coelho‐Júnior, H. J., Damiano, F. P., Bucci, C., & Marzetti, E. (2022) · Cells · doi:10.3390/cells11040675 · Cited by 30
Gu, X., Meng, H., Peng, C., Lin, S., Li, B., Zhao, L., Yang, X., Wang, G., Cai, W., Zhou, J., et al. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1308 · Cited by 25
Counteracting Immunosenescence—Which Therapeutic Strategies Are Promising?
Hieber, C., Grabbe, S., & Bros, M. (2023) · Biomolecules · doi:10.3390/biom13071085 · Cited by 30
Guo, H., Chen, J., Yu, H., Dong, L., Yu, R., Li, Q., Song, J., Chen, H., Zhang, H., Pu, J., et al. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110864 · Cited by 28
Du, M., Duan, J., Zhang, C., Yang, H., Guan, X., Zhong, W., Liu, Y., Li, Z., Cheng, Y., Zhou, Y., et al. (2019) · Cell Biology International · doi:10.1002/cbin.11205 · Cited by 27
Therapeutic Targeting of IL-11 for Chronic Lung Disease
Kortekaas, R. K., Burgess, J. K., van Orsoy, R., Lamb, D. J., Webster, M. J., & Gosens, R. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.01.007 · Cited by 26
“A recent publication showed induced expression of fibrotic genes ACTA2, COL1A1, COL1A2, and fibronectin 1 following treatment of healthy human cell line fibroblasts with conditioned medium from senescent human cell line fibroblasts, suggesting SASP to be a key contributor to the disease phenotype [56].”
BackgroundInfluentialLee, S. H., Yang, J.-H., Park, U., Choi, H., Kim, Y. S., Yoon, B., Han, H.-J., Kim, H.-T., Um, S., & Kim, E.-J. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01012-1 · Cited by 36
Salminen, A. (2023) · Biogerontology · doi:10.1007/s10522-023-10072-9 · Cited by 30
“Senescent fibroblasts are pro-inflammatory and pro-fibrotic cells and thus cellular senescence augments fibrosis in tissues (Tigges et al. 2014; Schafer et al. 2017; Hernandez-Gonzalez et al. 2021).”
BackgroundThe role of autoantibodies in bridging obesity, aging, and immunosenescence
Valentino, T. R., Chen, N., Makhijani, P., Khan, S. M., Winer, S., Revelo, X. S., & Winer, D. A. (2024) · Immunity & Ageing · doi:10.1186/s12979-024-00489-2 · Cited by 28
“Additionally, treating fibroblasts with culture media taken from senescent cells resulted in greater expression in pro-fibrotic genes [201], suggesting that senescence factors can promote fibrosis.”
Understanding and targeting senescence in kidney disease
Chanvillard, L., Mason, T., & Ferenbach, D. A. (2025) · Clinical Kidney Journal · doi:10.1093/ckj/sfaf190 · Cited by 32
Radiation-Induced Senescence Bystander Effect: The Role of Exosomes
Elbakrawy, E. M., Bains, S. K., Bright, S. J., AL-Abedi, R., Mayah, A., Goodwin, E. H., & Kadhim, M. A. (2020) · Biology · doi:10.3390/biology9080191 · Cited by 29
“Cellular senescence is triggered by various factors such as telomere attrition, enhanced oxidative stress, and accumulation of DNA damage [1].”
Backgroundp16-3MR: A Novel Model to Study Cellular Senescence in Cigarette Smoke-Induced Lung Injuries
Kaur, G., Sundar, I. K., & Rahman, I. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094834 · Cited by 29
An Integrative Multiomics Framework for Identification of Therapeutic Targets in Pulmonary Fibrosis
Arif, M., Basu, A., Wolf, K. M., Park, J. K., Pommerolle, L., Behee, M., Gochuico, B. R., & Çınar, R. (2023) · Advanced Science · doi:10.1002/advs.202207454 · Cited by 29
Yang, L., Hong, X., Gilbertsen, A. J., Smith, K. A., Racila, E. V., Bitterman, P. B., & Henke, C. A. (2023) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00028.2023 · Cited by 29
Strategic outline of interventions targeting extracellular matrix for promoting healthy longevity
Park, J. Y. C., King, A., Björk, V., English, B. W., Fedintsev, A., & Ewald, C. Y. (2023) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00060.2023 · Cited by 33
INK4a/ARF Expression Impairs Neurogenesis in the Brain of Irradiated Mice
Lê, O., Palacio, L., Bernier, G., Batinic̈‐Haberle, I., Hickson, G. R. X., & Beausejour, C. M. (2018) · Stem Cell Reports · doi:10.1016/j.stemcr.2018.03.025 · Cited by 26
“Clearance of p16INK4a-Expressing Cells Does Not Restore Neurogenesis Accumulation of p16INK4a-expressing cells was recently shown to contribute to the development of various pathologies and aging (Baker et al., 2016; Oubaha et al., 2016; Schafer et al., 2017).”
BackgroundBleomycin induces senescence and repression of DNA repair via downregulation of Rad51
Chen, F., Zhao, W., Du, C., Chen, Z., Du, J., & Zhou, M. (2024) · Molecular Medicine · doi:10.1186/s10020-024-00821-y · Cited by 28
A new clinical age of aging research
Zhang, Z., Yang, R., Zi, Z., & Liu, B. (2024) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2024.08.004 · Cited by 28
Li, Y., Yin, H., Yuan, H., Wang, E., Wang, C., Li, H., Geng, X., Zhang, Y., & Bai, J. (2024) · BMC Pulmonary Medicine · doi:10.1186/s12890-024-03260-x · Cited by 27
“Naïve PLFs were treated with media collected from 13 month PLFs, or the control MEM medium for 72 h, then collected the naïve PLFs for PCR analysis of senescence related genes [45].”
MethodAnti-senescence therapies: a new concept to address cardiovascular disease
Stojanović, S. D., Thum, T., & Bauersachs, J. K. (2025) · Cardiovascular Research · doi:10.1093/cvr/cvaf030 · Cited by 34
Ozdemir, S. A., Faizan, M. I., Kaur, G., Shaikh, S. B., Islam, K. U., & Rahman, I. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26199687 · Cited by 34
Elewa, Y. H. A., Ichii, O., Takada, K., Nakamura, T., Masum, M. A., & Kon, Y. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00271 · Cited by 23
“Due to the difficulties in studying the pathogenesis of lung fibrosis in humans, different animal models of pulmonary fibrosis have been developed to investigate potential therapies for IPF (9).”
BackgroundInfluentialA Senescence Bystander Effect in Human Lung Fibroblasts
Waters, D. W., Schuliga, M. J., Pathinayake, P. S., Wei, L., Tan, H.-Y., Blokland, K. E. C., Jaffar, J., Westall, G. P., Burgess, J. K., Prêle, C. M., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9091162 · Cited by 26
“Senescent fibroblasts had previously been identified in histological sections of IPF lung [9,10].”
BackgroundResultMukherjee, A., Epperly, M. W., Fisher, R., HOU, W., Shields, D. S., Wang, H., Greenberger, J. S., & Ortiz, L. A. (2021) · In Vivo · doi:10.21873/invivo.12601 · Cited by 25
Evidence of telomere attrition and a potential role for DNA damage in systemic sclerosis
Usategui, A., Municio, C., Arias‐Salgado, E. G., Martín, M. J., Fernández-Varas, B., Rey, M. J. D., Carreira, P. E., Gonzalez, A., Criado, G., Perona, R., et al. (2022) · Immunity & Ageing · doi:10.1186/s12979-022-00263-2 · Cited by 24
Lung Pneumonitis and Fibrosis in Cancer Therapy: A Review on Cellular and Molecular Mechanisms
Xu, C., Najafi, M., & Shang, Z. (2022) · Current Drug Targets · doi:10.2174/1389450123666220907144131 · Cited by 29
Senotherapies: A novel strategy for synergistic anti-tumor therapy
Qi, X., Li, J., & Cao, J. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.103365 · Cited by 26
From the divergence of senescent cell fates to mechanisms and selectivity of senolytic drugs
L’Hôte, V., Mann, C., & Thuret, J. (2022) · Open Biology · doi:10.1098/rsob.220171 · Cited by 31
“5 μM navitoclax when added for 48 h after a 2-day etoposide withdrawal [36], whereas 10 μM navitoclax did not affect cell viability if added for 48 h after a longer 6-day etoposide withdrawal [1].”
BackgroundSenescent AECⅡ and the implication for idiopathic pulmonary fibrosis treatment
Zhang, T., Zhang, J., Lv, C., Li, H., & Song, X. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1059434 · Cited by 29
“senescence can alleviate fibrosis and extend the life spans of experimental animals (Baker et al., 2016; Schafer et al., 2017; Hohmann et al., 2019; Rhinn et al., 2019; Omori et al., 2020).”
BackgroundWu, Y., Hu, S. S., Zhang, R., Goplen, N. P., Gao, X., Narasimhan, H., Shi, A., Chen, Y. M., Li, Y., Zang, C., et al. (2023) · iScience · doi:10.1016/j.isci.2023.107197 · Cited by 28
Wrench, C., Baker, J. R., Monkley, S., Fenwick, P. S., Murray, L. A., Donnelly, L., & Barnes, P. J. (2023) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00419.2022 · Cited by 32
Wei, Z., Guo, H., Qin, J., Lu, S., Liu, Q., Zhang, X., Zou, Y., Gong, Y., & Shao, C. (2019) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2018.10.457 · Cited by 24
Demystifying pulmonary fibrosis
Jenkins, G. R. (2020) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00365.2020 · Cited by 24
“Short telomeres lead to a process of accelerated aging known as cellular senescence, and indeed cellular senescence is particularly associated with pulmonary fibrosis, raising the prospect that senolytics may be useful therapies in IPF (16, 48, 60).”
BackgroundZhong, W., Chen, W., Liu, Y., Zhang, J., Lu, Y., Wan, X., Qiao, Y., Huang, H., Zeng, Z., Li, W., et al. (2022) · The FASEB Journal · doi:10.1096/fj.202200406rr · Cited by 23
Auld, S. C., Sheshadri, A., Alexander‐Brett, J. M., Aschner, Y., Barczak, A. K., Basil, M. C., Cohen, K. A., Cruz, C. S. D., McGroder, C. F., Restrepo, M. I., et al. (2024) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202406-651st · Cited by 29
“As has been found in mouse models of IPF (255 – 257), viral-induced cellular senescence has also been implicated as contributing to fi brosis in COVID-19 (258).”
Yang, L. C., You, J., Yang, X., Jiao, R., Xu, J., Zhang, Y., Mi, W., Zhu, L., Ye, Y., Ren, R., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-57334-3 · Cited by 30
Caveolae, caveolin-1 and lung diseases of aging
Wicher, S. A., Prakash, Y. S., & Pabelick, C. M. (2019) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2019.1575733 · Cited by 23
“In addition, effective wound healing decreases with age [89,90].”
BackgroundSelf-citationRegulatory Mechanisms of Mitochondrial Function and Cardiac Aging
Lin, R., & Kerkelä, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041359 · Cited by 27
“Moreover, in bleomycin-induced lung fibrosis model, depletion of senescent fibroblasts by D+Q enhances pulmonary function and exercise capacity [35].”
BackgroundThe use of geroprotectors to prevent multimorbidity: Opportunities and challenges
Morsli, S., & Bellantuono, I. (2020) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2020.111391 · Cited by 28
Senescence and Aging: Does It Impact Cancer Immunotherapies?
Maggiorani, D., & Beausejour, C. M. (2021) · Cells · doi:10.3390/cells10071568 · Cited by 25
The potential of Senolytics in transplantation
Matsunaga, T., Iske, J., Schroeter, A., Azuma, H., Zhou, H., & Tullius, S. G. (2021) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2021.111582 · Cited by 22
Insights from Transcriptomics: CD163+ Profibrotic Lung Macrophages in COVID-19
Bhattacharya, M. (2022) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2022-0107tr · Cited by 26
“Alveolar epithelial cells have been noted to develop features of cellular senescence (13–15), a DNA damage response associated with replicative arrest and a secretory state known as the senescence-associated secretory profile, which has been shown to be profibrotic in animal models (13, 16).”
BackgroundZhang, X., Hu, X., Zhang, Y., Liu, B., Pan, H., Liu, Z., Yao, Z., Zhu, Q., Wu, C., & Shen, T. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-01821-6 · Cited by 24
Metadata
- Authors
- Schafer, M. J., White, T. A., Iijima, K., Haak, A. J., Ligresti, G., Atkinson, E. J., Oberg, A. L., Birch, J., Salmonowicz, H., Zhu, Y., Mazula, D. L., Brooks, R. W., Fuhrmann-Stroissnigg, H., Pirtskhalava, T., Prakash, Y. S., Tchkonia, T., Robbins, P. D., Aubry, M. C., Passos, J. F., Kirkland, J. L., Tschumperlin, D. J., Kita, H., & LeBrasseur, N. K.
- Affiliations
- Mayo Clinic (US)
- Newcastle University (GB)
- Scripps Research Institute (US)
- Corresponding author
- LeBrasseur, Nathan K.
- ORCID
- Venue
- Nature Communications
- Published
- 2017-02-23
- Volume
- 8
- Issue
- 1
- Pages
- 14532-14532
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC5331226
- OpenAlex
- W2591114726
- Cited by
- 1,613
- References
- 52
- Citations by year
- 2026: 195 · 2025: 205 · 2024: 193 · 2023: 193 · 2022: 192 · 2021: 181 · 2020: 176 · 2019: 128 · 2018: 107 · 2017: 42
- FWCI
- 91.58
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Newcastle University ePrints (Newcastle Univesity) (cc-by)
- Funders
- Mayo Clinic (UL1-TR000135)
- Glenn Foundation for Medical Research
- Louisiana Transportation Research Center
- Georgia Clinical and Translational Science Alliance (UL1 TR000135)
- Noaber Foundation
- Fondation pour la Recherche Médicale
- National Institutes of Health (UL1TR000135, 2r01hl092961-13)
- Directorate for Biological Sciences
- Biotechnology and Biological Sciences Research Council (BB/K017314/1, BB/H022384/1)
- National Institute on Aging (R01AG053832, R01AG013925, R37AG013925)
- National Heart, Lung, and Blood Institute (R01-HL-092961)
- National Center for Advancing Translational Sciences
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Keywords
- cellular senescence, idiopathic pulmonary fibrosis, senolytics, senescence-associated secretory phenotype, senescent fibroblasts, p16, bleomycin-induced lung injury, interstitial pulmonary fibrosis, suicide gene therapy, lung function
- MeSH terms
- Animals, Bleomycin, Fibroblasts, Humans, Lung, Male, Biomarkers, Cellular Senescence, Cyclin-Dependent Kinase Inhibitor p16, Proteome, Mice, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.